The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population

Thrombosis Research

Volumn 130, Issue 3, 2012, Pages

  Isordia Salas, Irma ^a   Olalde Román, Marcos Jaciel ^b   Santiago Germán, David ^a,c   De La Peña, Norma Corona ^a   Valencia Sánchez, Jesús Salvador ^b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b HOSPITAL DE CARDIOLOGÍA   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Acetylsalicylic; Clopidogrel; Platelets; Polymorphism

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CLOPIDOGREL; CYTOCHROME P450 3A5; GLYCOPROTEIN IIIA; ANTITHROMBOCYTIC AGENT; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CORONARY ARTERY THROMBOSIS; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEXICO; PERCUTANEOUS CORONARY INTERVENTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOCYTE AGGREGATION; TURBIDIMETRY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESISTANCE; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; MIDDLE AGED; PREVALENCE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ASPIRIN; COMORBIDITY; CYTOCHROME P-450 CYP3A; DRUG RESISTANCE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MALE; MEXICO; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; RECEPTORS, PURINERGIC P2Y12; RISK FACTORS; THROMBOSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84865267256     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.06.024     Document Type: Article

References (24)

1. P.J. Sharis, C.P. Cannon, and J. Loscalzo The antiplatelet effects of ticlopidine and clopidogrel Ann Intern Med 129 1998 394 405
2. V.L. Serebruanu, S.R. Steinhubl, P.B. Berger, A.I. Malinin, D.L. Bhatt, and E.J. Topol Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 45 2005 246 251
3. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
4. P.A. Gurbel, K.P. Bliden, K. Guyer, P.W. Cho, K.A. Zaman, and R.P. Kreutz Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study J Am Coll Cardiol 46 2005 1820 1826
5. P.A. Gurbel, and U.S. Tantry Clopidogrel resistance? Thromb Res 120 2007 311 321
6. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramírez, C. Barrera-Ramirez, and M. Sabaté Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting Thromb Res 115 2005 101 108
7. S. Matetzky, B. Shenkman, V. Guetta, M. Shechter, R. Bienart, and I. Goldenberg Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
8. P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem, and J. Schuetz Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 27 2001 383 391
9. J.W. Suh, B.K. Koo, S.Y. Zhang, K.W. Park, J.Y. Cho, and I.J. Jang Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel CMAJ 174 2006 1715 1722
10. K.A. Kim, P.W. Park, and J.Y. Park Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects Eur J Clin Pharmacol 64 2008 589 597
11. P. Fontana, A. Dupont, S. Gandrille, C. Bachelot-Loza, J.L. Reny, and M. Aiach Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects Circulation 108 2003 989 995
12. P. Staritz, K. Kurz, M. Stoll, E. Giannitsis, H.A. Katus, and B.T. Ivandic Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene Int J Cardiol 133 2009 341 345
13. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramírez, U. Cavallari, and E. Trabetti Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease Thromb Res 116 2005 491 497
14. D.J. Angiolillo, A. Fernandez- Ortiz, E. Bernardo, F. Alfonso, M. Sabaté, and C. Fernández PIA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation Blood Coagul Fibrinolysis 15 2004 89 93
15. A.Y. Gasparyan, T. Watson, and G.Y. Lip The role of aspirin in cardiovascular prevention: implications of aspirin resistance J Am Coll Cardiol 51 2008 1829 1843
16. A.Y. Gasparyan Aspirin and clopidogrel resistance: methodological challenges and opportunities Vasc Health Risk Manag 6 2010 109 112
17. A. Lepäntalo, K.S. Virtanen, J. Heikkilä, U. Wartiovaara, and R. Lassila Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions Eur Heart J 25 2004 476 483
18. T. Cuisset, C. Frere, J. Quilici, P.E. Morange, L. Camoin, and L. Bali Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response Thromb Res 123 2009 597 603
19. E.I. Lev, R.T. Patel, S. Guthikonda, D. Lopez, P.F. Bray, and N.S. Kleiman Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel Thromb Res 119 2007 355 360
20. T. Cuisset, C. Frere, J. Quilici, P.E. Morange, N. Saut, and M. Lambert Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome Thromb Res 120 2007 893 899
21. S. Namazi, J. Kojuri, A. Khalili, and N. Azarpira The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients Biochem Pharmacol 83 2012 903 908
22. C. Frere, T. Cuisset, P.E. Morange, J. Quilici, L. Camoin-Jau, and N. Saut Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome Am J Cardiol 101 2008 1088 1093
23. D. Santiago-Germán, A. Leaños-Miranda, E. García-Latorre, G. Borrayo-Sánchez, A. Majluf-Cruz, and I. Isordia-Salas Platelet glycoprotein IIIA PIA2 polymorphism is associated with ST elevation acute myocardial infarction in young Mexican population J Thromb Thrombolysis 33 2012 389 396
24. B. Labarthe, P. Théroux, M. Angioï, and M. Ghitescu Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug J Am Coll Cardiol 46 2005 638 645